This morning, Leerink Swann increased its price target on shares of Pfizer (NYSE:PFE) to $28.50 as international sales of Lyrica could boost earnings at the pharmaceutical giant. In the report, Leerink increased its EPS estimates and maintained its market perform rating. Shares of Pfizer were lower by 1.1% despite the news.
Oppenheimer increased its price target on shares of Verizon (NYSE:VZ) to $56 following the $130 billion buyout deal with Vodaphone (VOD). In the report, Oppenheimer reiterated its outperform rating. Shares of Verizon were lower on Tuesday, falling 2.4%.
And Lazard increased its EPS estimates on shares of Micron (NASDAQ:MU) through 2014 as recent comments by management suggest the market for memory chips remains strong. Lazard maintained its neutral rating in the report. Shares of Micron were higher by 2.7% on the news.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.